Imbria Pharmaceuticals has secured $57.5m in a Series B funding round to support the progression of ninerafaxstat through a double-blind Phase IIb FORTITUDE-HCM trial in non-obstructive hypertrophic cardiomyopathy (nHCM).
Renovaro Biosciences has completed its merger with AI-driven drug discovery and precision neurology firm, BioSymetrics.
4P-Pharma spin-off 4Moving Biotech (4MB) has received €7.6m ($8.3m) in funding from the France 2030 plan to expedite the clinical development of 4P004 for knee osteoarthritis, currently in a Phase IIa clinical trial.
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Amgen’s humanised monoclonal antibody Uplizna (inebilizumab-cdon) to treat the adult population with immunoglobulin G4-related disease (IgG4-RD), an immune-mediated inflammatory condition that impacts several organs.
The US Food and Drug Administration (FDA) has granted clearance for an investigational new drug (IND) application of Epicrispr Biotechnologies’ EPI-321, intended for treating genetic neuromuscular condition, facioscapulohumeral muscular dystrophy (FSHD).
Pharvaris has secured orphan designation from the European Commission (EC) for deucrictibant, an investigational drug for treating bradykinin-mediated angioedema.
As a part of a broader investment round, Beyond Air’s subsidiary NeuroNOS has received an initial equity financing of $2m from private investors, aimed at expediting the preclinical development of its small-molecule drug for paediatrics with autism.
A collaborative effort between Duke-NUS Medical School and the National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) has led to the launch of the joint research centre named Systems Metabolomics Centre (SysMeC), aimed at metabolomics research.
The US Food and Drug Administration (FDA) has granted approval for Novartis’ Fabhalta (iptacopan), intended to minimise proteinuria in the adult population with C3 glomerulopathy (C3G).
Contract development and manufacturing organisation (CDMO) Porton Advanced has announced a partnership with Eureka Therapeutics to expedite the worldwide clinical development of T-cell therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.